The Nature of Homologousness: How Proteins Are Like Family and Where Science Draws the Line

In biology, there’s probably no concept like 'homology' that’s seen as a quiet assumption behind most molecular biology and protein research, yet it’s often oversimplified or misunderstood. It started purely as an idea: two genes or proteins that come from a common ancestor. But in everyday scientific work and industry practice, 'homology' has been boiled down a lot: first, it got equated with 'sequence similarity,' and then stretched further to include grouping, functional consistency, and even things like druggability or other quality equivalences. If any of these match, people just go with it. Human and mouse homologous proteins can have very similar sequences, yet be very different in catalytic efficiency, substrate preference, and thermal stability; proteins from the same family can either fold into the same group or bind totally different ligands. The fact that they share a common origin is just a clue, not an argument against anything; it’s meant to be a starting point for research but is often treated like a conclusion.

1. The Three Layers of True Frontiers of Sameness

Three Scientific Boundaries of Homology Analysis

From the definition of 'Jian,' homology basically refers to a person's fate. The key idea is figuring out that two proteins come from the same ancestor—based on the idea that 'the essence is sequence similarity, there isn't really an actual degree of sameness.' In everyday life, everything is kind of similar in essence, it doesn’t come from one single source or body.

With that in mind, homology should be considered across three separate layers in research and industry, each with its own entry point. Treating the layers as the same can lead to misunderstandings in practice.

**Layer 1: Structural boundaries:** Think of it as a conservative framework, not an exact shape.

Homologous proteins usually share a core fold, which is widely accepted in structural biology. But conservatism only applies to the core skeleton; things like changes in loop lengths due to insertions or deletions, surface charge patterns, and flexible domain movements become more pronounced with evolutionary distance, changing how molecules interact.

**Layer 2: Functional boundary:** Proteins from the same family aren't necessarily functionally identical.

Function usually depends on a few key residues—like active sites, binding spots, and core interface residues—not on total sequence similarity. Even within the same family, swapping out key points can completely change the protein’s activity, efficiency, and roles.

**Layer 3: System boundary:** Just because proteins share a sequence origin doesn’t mean they perform the same way in different environments.

Factors like folding efficiency, solubility, and activity depend on the host cell’s internal environment. Even with identical sequences, expressing them in different species with different chaperones, oxidation levels, codon preferences, and membrane compositions can produce very different outcomes.

When you look at these three layers, that’s how they’re usually applied.

2. Three major cognitive blind spots in homology applications

If there really is one, then three people are the foundation.

One skill is blind: forcing your way across boundaries—but the two limitations are pretty similar.

This is one of the most common misunderstandings. The people in the classics, their authors are the guiding principles. But those who achieve success and make a career still have remnants of the past, even if they are in foreign lands.

Cytochrome color indeed refers to a biological trait, and it’s the classic rule: the sequence and properties of the same family member can reach the highest level, even transcendent levels, but the unique substances produced beneath them can be very different. Even if a single key is useless, it can still become a standard practice and replace medicine in transformations. Relying on global homology inference is basically like blind men touching an elephant and is a core reason why drug metabolism predictions and enzyme substrate screenings often go off track.

There are two types of blind spots: crossing boundaries—building models and implementing them from the same source.

Without experimental structures, homology modeling is a way to get 3D information, but accuracy really depends on how similar the template is to the target. In traditional homology modeling, listing the same sexual attribute is considered a critical dividing line: encounters above the site threshold, with core scaffold accuracy usually determining species traits, showing distinct features and clear signs of surface damage. By regulation, model accuracy should match distinctions and be confirmed experimentally.

But many R&D teams force models when sequence identity isn’t enough and apply them directly to downstream computations like molecular docking or virtual screening. As for her husband, she isn’t like him. If you follow the Way again, form is just form.

Then there are three blind spots: crossing system boundaries.

Expressed in different sources, transferring prokaryotic homologous genes into eukaryotic hosts—or mammalian genes into bacterial systems—can make a big difference. Even if sequences are complete and consistent, differences in expression, range, folding efficiency, and post-translational modifications can make the results even more different.

The host cell’s internal environment—chaperone systems, redox potential, membrane composition, codon preferences—is different from the original host, and these system factors often influence protein activity more than the sequence itself. Many industrial enzyme or recombinant protein projects just use existing expression systems because of 'sequence homology,' ignoring whether the host’s own traits match. Eventually, 'sequence homology' results in lost activity and delays projects for months.

3. Breaking the Chessboard: Going from vague homology guesses to precise mapping.

The three main blind concepts come from a natural origin. It's a traditional method that simplifies similarities using a percentage scale and uses that scale to predict everything about them. This makes people's complaints shake them and moves them, with phrases like 'sharing the same origin,' all coming down to a precise nature. ™ It's about understanding the sequence structure of 'Xiao ™ energy'—the framework that combines merit and energy sharing the same origin, which is basically the idea of whether it exists or not.

Homology Identification System

3.1. Functional Constraint Map: Break Functional Blind Spots and Assess Similarity with a Functional Lens

To address the misconception of "high similarity but functional divergence," deep learning models can accurately label the functional weight of each residue based on multiple sequence alignments: which are essential catalytic sites and binding hotspots, which are structural core residues maintaining folding, and which surface regions can freely mutate.

Even if two sequences share an overall similarity of 85%, a critical change in a functionally essential residue can result in completely different functions; conversely, sequences with only 60% overall similarity can have highly overlapping functions if the core functional sites are fully conserved. This "function-oriented homology analysis" upgrades traditional global similarity assessment to residue-level alignment in key functional regions, greatly improving the accuracy of functional inference.

3.2. High-Precision Structure Prediction: Break Structural Blind Spots and Escape Experimental Template Dependence

AI structure prediction tools like AlphaFold2, ESMFold, and Protenix have greatly overcome the traditional limitation that modeling required known experimental structures of homologous proteins. Even if the target sequence shares less than 20% identity with all known structures, as long as its homologous family has sufficiently deep multiple sequence alignment (MSA) information, AlphaFold2 can generate high-confidence 3D models based on co-evolution signals.

It should be noted that for 'orphan proteins'—those with almost no homologs in known sequence databases—the quality of structure prediction significantly drops. This remains an active frontier in AI protein structure prediction.

More importantly, these models provide confidence scores for each residue (pLDDT) and residue-residue distance error estimates (PAE), allowing researchers to clearly distinguish highly reliable structural regions from flexible uncertain regions. Homology is no longer the sole source of structural information but has become one reference dimension for validating evolutionary relationships.

3.3 Cross-Host Expression Prediction: Break System Blind Spots and Place Homology in Real Biological Context

To tackle the blind spot that "homologous genes ≠ homologous expression," AI platforms can learn from massive heterologous expression experimental data to build nonlinear mapping models between sequence features and expression level, solubility, and folding efficiency. By inputting a target sequence, one can predict its expression performance in a specific host and receive targeted optimization suggestions—including codon optimization, signal peptide replacement, and chaperone co-expression strategies.

This capability elevates homology analysis from the "pure sequence level" to the "system level": it's no longer just about whether sequences are similar, but whether the sequence is "compatible" in the target host environment.

4. Elevating Homology: From Inference Basis to Designing the Chassis

Homology From Inference Basis to Design Chassis

When AI grants homology analysis unprecedented precision and dimensionality, its value is no longer limited to 'finding a similar reference starting point,' but expands into the foundational design platform for protein engineering.

In drug development, accurately analyzing the homology differences between human and model animal targets allows for early assessment of pharmacological and toxicological deviations caused by species differences, preemptively reducing the risk of misinterpreting preclinical data. Homologous variants of the same target in different disease subtypes can also potentially become biomarkers for differentiated treatments.

In enzyme engineering, based on sequence-structure-function relationships within homologous families, AI can reconstruct ancestral sequences and design 'hybrid homologs' that do not exist in nature, achieving targeted optimization in catalytic efficiency, stereoselectivity, and substrate spectrum. This rational design based on evolutionary information has a much higher success rate than random mutation screening and is currently a mainstream, efficient strategy for industrial enzyme modification.

In antibody discovery, homology analysis can help screen for new scaffolds with epitopes similar to known antibodies but higher affinity. It can also guide targeted mutations at immunogenic risk sites while preserving binding activity, completing antibody humanization optimization.

Homology is no longer a static classification label; it is a dynamic, designable map. Within the same evolutionary branch, AI can clearly mark which regions are untouchable functional conserved zones, which are freely mutable variable zones, and which are key mutation sites leading to new functions. In the MatwingsVenus™ (Xiaowu™) intelligent protein design system, this set of evolutionary constraints derived from homologous families is indeed one of the core underlying logics for directed evolution and sequence design.

Conclusion

Homology is one of humanity’s oldest coordinate systems for understanding the protein world. It helped us find the first key and open the first door. But in the vast world beyond that door, relying solely on the vague guidance of ‘distant relatives’ is far from enough — we need precise maps, quantifiable risk indicators, and actionable design plans.

AI has not overturned the value of homology; it has restored it to what it should be: no longer a vague percentage number, no longer the inertial inference that ‘similar equals homologous, homologous equals same function,’ but a hierarchical, verifiable, quantifiable, and designable evolutionary knowledge system. It transforms homology from a single research clue into the foundational platform supporting rational design.

When homology can be precisely dissected, multidimensionally quantified, and proactively designed, protein innovation is no longer a trial-and-error game of 'find something similar and try it,' but a rational engineering process of 'building new functions based on evolutionary principles.' This may be the deepest evolution of the century-old concept of homology in the AI era — evolving from interpreting the past to designing the future.